Fabtech Technologies Limited – Investor Presentation Summary
Key Operational Highlights
- Global turnkey solutions provider operating across 62 countries with focus on pharmaceutical, biotech and healthcare facilities
- 78% of revenue derived from MENA, GCC and ECO Zone markets
- Asset-light, integrated model combining in-house manufacturing and advanced project execution
- Key capabilities across Process Equipment & Containment Systems, Cleanrooms, and Purified Water & Distribution systems
Key drivers of operational performance:
Better project selection, procurement efficiency, execution quality, and scope mix driving margin expansion
Financial Highlights
Revenue: ₹74.98 Cr
EBITDA: ₹7.41 Cr
PAT: ₹4.21 Cr
Contribution Margin: 46.7%
YoY/QoQ comparison:
- Revenue up 10.3% YoY
- Swung from ₹6.13 Cr loss to ₹4.21 Cr profit YoY
- Contribution margin expanded 910 basis points YoY
- Employee costs down 2.8% to ₹10.22 Cr
- Finance costs down 35.9% to ₹0.84 Cr
Drivers of financial performance:
Higher contribution margin due to better project selection, procurement efficiency, execution quality, and scope mix
Post-IPO utilization of funds reducing finance costs
Key Risks:
Seasonal concentration in H2 characteristic of EPC sector
Severe regional pressure in some markets
Project timing and execution cycle variations
Geographical Revenue Split
International revenue share: ~55%
Regional Breakdown:
- Saudi Arabia: ₹17.13 Cr (+130% growth)
- Africa: ₹27.93 Cr (Morocco and Kenya combined)
- Rest of world: 29.6%
- UAE: 27.9%
- India: 10.0%
- Kenya: 9.6%
- Morocco: 4.8%
Strategic & R&D Initiatives
Investments in becoming local market-by-market through FTS Cleanroom Systems LLC and strategic joint ventures
Focus on precision-controlled environments in-house across Process, Air & Water capabilities
Expected impact on growth:
Market localization strategy driving growth in Saudi Arabia (+130%) and African markets
Strategic Rationale:
Expanding into high-growth GCC and African markets with pharmaceutical self-reliance focus post-COVID
Reducing dependency on imports and fragmented suppliers
Industry Trends & Business Environment
Macro/Industry Trends:
- Post-COVID MEA region focus on pharmaceutical self-reliance
- Biologics and specialty pharma capex accelerating
- Healthcare infrastructure investment in GCC and Africa
- Regulatory pressure driving facility upgrades globally
- China+1 strategies increasing manufacturing diversity
Impact on Company:
Accelerating growth trajectory in target markets
Strong order pipeline of ₹9,300+ Cr
Management Commentary & Growth Outlook
Strategic Outlook: "Our aspiration is not simply to become larger. It is to become stronger, more resilient and more admired — an institution that commands trust and stands as a global benchmark in life sciences engineering" - Naushad Panjwani, Chairman
FY Guidance: Expected 20-25% YoY organic growth for FY27 based on order pipeline and business visibility
Growth Expectations: Q2 steady, H2 stronger with large-ticket opportunities in Africa
Risks and Opportunities: Seasonal patterns in EPC business with H2 typically stronger
Capital Allocation Philosophy
- Capital deployed against execution priorities
- Acquisitions considered based on strategic fit rather than pace
- Idle capital optimization reviewed every quarter
Corporate Structure
Fabtech Group structure includes:
- 100% ownership in KSA operations
- 100% ownership in UAE operations (FTS Cleanroom Systems LLC)
- 49% ownership in another entity
- ~16% ownership in another entity
- 33.33% ownership in joint ventures